These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 16597474

  • 1. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
    Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA.
    Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
    [Abstract] [Full Text] [Related]

  • 2. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM.
    Cancer; 2002 Nov 15; 95(10):2160-8. PubMed ID: 12412170
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
    Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP, David Walde PL, Rudinskas LC, Rahim YH, Rodgers A, Pond GR, Shepherd FA.
    Clin Lung Cancer; 2003 Sep 15; 5(2):107-12. PubMed ID: 14596693
    [Abstract] [Full Text] [Related]

  • 4. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
    Charpidou A, Hatzidarellis EP, Alamara C, Dilana K, Pantazopoulos K, Kotteas E, Georgatou N, Syrigos KN.
    In Vivo; 2006 Sep 15; 20(4):553-7. PubMed ID: 16900789
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
    Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ.
    Cancer; 2007 Mar 01; 109(5):924-32. PubMed ID: 17285598
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH.
    Cancer J Sci Am; 2000 Mar 01; 6(1):34-9. PubMed ID: 10696737
    [Abstract] [Full Text] [Related]

  • 10. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 01; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 11. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M, Ochi Y, Kadota A, Akusawa H, Kisohara A, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 2000 May 01; 7(2):305-10. PubMed ID: 10671676
    [Abstract] [Full Text] [Related]

  • 12. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
    Lebeau B, Chouaïd C, Baud M, Masanès MJ, Febvre M.
    Lung Cancer; 2010 Feb 01; 67(2):188-93. PubMed ID: 19394109
    [Abstract] [Full Text] [Related]

  • 13. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer].
    Saito H, Kawatsu H, Saka H, Yamamoto M, Takagi E, Tsunekawa H, Kawachi H, Nagura E, Sakai S, Nishiwaki K.
    Gan To Kagaku Ryoho; 1988 Jun 01; 15(6):1909-13. PubMed ID: 2838000
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
    Chamberlain MC, Glantz MJ.
    Neurosurgery; 2008 Oct 01; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
    [Abstract] [Full Text] [Related]

  • 16. [Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer].
    Kawahara M, Tsuruta M, Furuse K, Arai R, Kodama N, Yamamoto M, Kubota K, Nakai R, Ogawara M.
    Gan To Kagaku Ryoho; 1988 Mar 01; 15(3):457-62. PubMed ID: 2831819
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
    Littlewood TJ, Smith AP, Anderson G, Chappell AG, James KW.
    Eur J Respir Dis; 1985 Oct 01; 67(4):294-300. PubMed ID: 3000808
    [Abstract] [Full Text] [Related]

  • 19. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, North-Eastern German Society of Gynecological Oncology.
    Cancer Chemother Pharmacol; 2009 Aug 01; 64(3):585-91. PubMed ID: 19156414
    [Abstract] [Full Text] [Related]

  • 20. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG, Froudarakis ME, Bouros D, Koukourakis MI.
    Anticancer Res; 2008 Aug 01; 28(2B):1349-54. PubMed ID: 18505077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.